Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Purpose
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.
Conditions
- Clear Cell Renal Cell Carcinoma
- Renal Cell Carcinoma (RCC)
- Stage II Renal Pelvis Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- • Histologically confirmed diagnosis of RCC with clear cell component with or
without sarcomatoid features following complete resection of the primary tumor
(radical or partial nephrectomy)
- Note: Patients with microscopically positive soft tissue or vascular margins
without gross residual disease are permitted
- Intermediate-high risk RCC:
- pT2 grade 4 or sarcomatoid features, N0M0
- pT3 any grade N0, M0
- High-risk RCC
- pT4, any grade, N0, M0
- pT, any stage., any grade, N+, M0
- cM1 no evidence of disease (NED) RCC
- Participants who have had resection of primary tumor (radical or
partical nephrectomy) and resection or definitive radiation or
ablation of solid, isolated, soft tissue metastases (excluding brain
and bone lesions) at the time of primary tumor removal (synchronous)
or ≤1 year from primary tumor removal (metachronous)
- Surgery (radical or partial nephrectomy or metastasectomy or
ablation) > 4 weeks but =< 16 weeks prior to study registration
with no ongoing complications from surgery
- No evidence of disease at time of randomization as assessed by
investigator by either CT or MRI scan of the brain and chest,
abdomen and pelvis
- No prior systemic treatment for RCC
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status =<
2 (or Karnofsky >= 60%)
- Absolute neutrophil count (ANC) >= 1,000/mm^3
- Platelet count >= 100,000/mm^3
- Hemoglobin >= 8 g/dL
- Total bilirubin =< 3 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic
transaminase [SGOT])/alanine aminotransferase (ALT) (serum
glutamate pyruvate transaminase [SGPT]) =< 3 x upper limit of
normal (ULN)
- Calculated (calc.) creatinine clearance >= 30 mL/min (using
Cockcroft Gault equation or the estimated glomerular filtration
rate from the modification of diet in renal disease trial)
- Urine protein =< 1+ on urine analysis (UA) or urine protein
creatinine ration (UPCR) < 2mg/mg
- Not pregnant and not nursing, because this study involves an
agent that has known genotoxic, mutagenic and teratogenic
effects. Therefore, for women of childbearing potential only, a
negative pregnancy test is required =< 14 days prior to
registration
- HIV status: HIV-infected patients on effective anti-retroviral
therapy with undetectable viral load within 6 months are
eligible for this trial
- Hepatitis
- Hepatitis B: For patients with evidence of chronic hepatitis B virus (HBV)
infection, the HBV viral load must be undetectable on suppressive therapy, if
indicated. Patients with resolved HBV infection, defined as positive hepatitis
B core antibody (anti-HBc) and negative hepatitis B surface antigen (HbsAg),
are eligible
- Hepatitis C: Patients with a history of hepatitis C virus (HCV) infection must
have been treated and cured. For patients with HCV infection who are currently
on treatment, they are eligible if they have an undetectable HCV viral load
- Cardiac Disease: Patients with known history or current symptoms of
cardiac disease, or history of treatment with cardiotoxic agents, should
have a clinical risk assessment of cardiac function using the New York
Heart Association Functional Classification. To be eligible for this
trial, patients should be class IIB or better
- No history of myocarditis
- No history of clinically significant pneumonitis
- No uncontrolled hypertension (systolic blood pressure [BP] > 150 mm Hg or
diastolic BP > 90 mm Hg) documented on 2 consecutive measurements taken at
least 2 hours apart
- No serious non-healing wound, ulcer or bone fracture within 28 days prior
to registration
- No serious/active infection requiring parenteral antibiotics
- No moderate or severe hepatic impairment (child-Pugh B or C)
- No significant bleeding disorders within 1 month prior to registration,
for example:
- Hematemesis, hematochezia or other gastrointestinal bleeding grade 3 or higher
- Hemoptysis of pulmonary bleeding grade 3 or higher
- Hematuria or other genitourinary bleeding grade 3 or higher
- No history of allogeneic organ transplantation
- No history of allergy of hypersensitivity to study drugs or components
- No condition requiring systemic treatment with either corticosteroid (> 10
mg daily or prednisone equivalent) within 14 days of treatment initiation
or other immunosuppressive medications within 30 days of randomization.
Inhaled or topical steroids and adrenal replacement doses ≤10 mg daily
prednisone equivalent are permitted in absence of active autoimmune
disease
- No active peptic ulcer disease, inflammatory bowel disease, ulcerative
colitis or other gastrointestinal condition associated with increased risk
of perforation; history of abdominal fistula, gastrointestinal perforation
or intra-abdominal abscess within 4 weeks prior to registration
- Patients with a prior or concurrent malignancy whose natural history or
treatment does not have the potential to interfere with the safety or
efficacy assessment of the investigational regimen are eligible for this
trial
- No patients with a history of autoimmune disease that has required
systemic treatment in the past 2 years (i.e., with use of disease
modifying agents, corticosteroids > 10 mg/day, or immunosuppressive drugs)
with the following exceptions:
- Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency) is not considered a
form of systemic treatment and is allowed
- Brief (<7 days) use of systemic corticosteroids is allowed when use is
considered standard of care
- Patients with vitiligo, psoriasis, type 1 diabetes mellitus, hypothyroidism, or
resolved childhood asthma/atopy will not be excluded
- Patients requiring intermittent use of bronchodilators, inhaled steroids, or
local steroid injections will not be excluded
- Patients with hypothyroidism that is stable with hormone replacement or
Sjögren's syndrome will not be excluded • Chronic concomitant treatment with
strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14
days prior to the start of study treatment
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm 1 (Pembrolizumab) |
Patients receive pembrolizumab IV on days 1 and 43 of each cycle, or on days 1, 22, 43 and 64 of each cycle. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study. |
|
|
Experimental Arm 2 (pembrolizumab + tivozanib) |
Patients receive pembrolizumab IV on days 1 and 43 of each cycle and tivozanib PO QD on days 1-21, days 29-49, and days 57-77 of each cycle for up to 6 months. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study. |
|
Recruiting Locations
Phoenix 5308655, Arizona 5551752 85004
Tucson 5318313, Arizona 5551752 85719
Tucson 5318313, Arizona 5551752 85719
Jonesboro 4116834, Arkansas 4099753 72401
Little Rock 4119403, Arkansas 4099753 72205
Site Public Contact
501-686-8274
Auburn 5325223, California 5332921 95602
Beverly Hills 5328041, California 5332921 90211
Duarte 5344147, California 5332921 91010
Irvine 5359777, California 5332921 92612
Irvine 5359777, California 5332921 92618
Site Public Contact
877-467-3411
La Jolla 5363943, California 5332921 92093
Lancaster 5364940, California 5332921 93534
Los Angeles 5368361, California 5332921 90033
Los Angeles 5368361, California 5332921 90033
Site Public Contact
323-865-0451
Los Angeles 5368361, California 5332921 90048
Site Public Contact
310-423-8965
Modesto 5373900, California 5332921 95355
Newport Beach 5376890, California 5332921 92663
Site Public Contact
323-865-0451
Orange 5379513, California 5332921 92868
Palo Alto 5380748, California 5332921 94301
Roseville 5388881, California 5332921 95661
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95817
Site Public Contact
916-734-3089
San Diego 5391811, California 5332921 92103
San Francisco 5391959, California 5332921 94115
San Mateo 5392423, California 5332921 94401
Santa Cruz 5393052, California 5332921 95065
Sunnyvale 5400075, California 5332921 94086
Torrance 5403022, California 5332921 90503
Site Public Contact
877-467-3411
Torrance 5403022, California 5332921 90505
Upland 5404915, California 5332921 91786
Vallejo 5405380, California 5332921 94589
Aurora 5412347, Colorado 5417618 80045
Site Public Contact
720-848-0650
Colorado Springs 5417598, Colorado 5417618 80909
Site Public Contact
719-365-2406
Colorado Springs 5417598, Colorado 5417618 80920
Site Public Contact
719-364-6700
Denver 5419384, Colorado 5417618 80206
Fort Collins 5577147, Colorado 5417618 80524
Site Public Contact
970-297-6150
Fort Collins 5577147, Colorado 5417618 80528
Greeley 5577592, Colorado 5417618 80631
Highlands Ranch 5425043, Colorado 5417618 80129
Site Public Contact
720-848-0650
Lone Tree 5429208, Colorado 5417618 80124
Loveland 5579368, Colorado 5417618 80538
Site Public Contact
970-203-7083
Bridgeport 5282804, Connecticut 4831725 06606
Site Public Contact
860-972-4700
Derby 4832745, Connecticut 4831725 06418
Fairfield 4834157, Connecticut 4831725 06824
Fairfield 4834157, Connecticut 4831725 06824
Greenwich 4835395, Connecticut 4831725 06830
Guilford 4835512, Connecticut 4831725 06437
Hartford 4835797, Connecticut 4831725 06102
Site Public Contact
860-545-5363
Meriden 4838524, Connecticut 4831725 06451
Site Public Contact
866-662-5678
New Britain 4839292, Connecticut 4831725 06050
Site Public Contact
860-224-5660
New Haven 4839366, Connecticut 4831725 06520
Stamford 4843564, Connecticut 4831725 06902
Stamford 4843564, Connecticut 4831725 06904
Site Public Contact
203-323-8944
Torrington 4844309, Connecticut 4831725 06790
Trumbull 4844459, Connecticut 4831725 06611
Waterbury 4845193, Connecticut 4831725 06708
Waterford 8480031, Connecticut 4831725 06385
Millville 4143696, Delaware 4142224 19967
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19713
Rehoboth Beach 4144284, Delaware 4142224 19971
Washington D.C. 4140963, District of Columbia 4138106 20010
Site Public Contact
202-877-8839
Washington D.C. 4140963, District of Columbia 4138106 20037
Site Public Contact
202-741-2210
Gainesville 4156404, Florida 4155751 32610
Miami 4164138, Florida 4155751 33176
Site Public Contact
786-596-2000
Atlanta 4180439, Georgia 4197000 30303
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30308
Site Public Contact
888-946-7447
Atlanta 4180439, Georgia 4197000 30322
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30342
Site Public Contact
404-851-7115
Johns Creek 6331909, Georgia 4197000 30097
Boise 5586437, Idaho 5596512 83712
Coeur d'Alene 5589173, Idaho 5596512 83814
Fruitland 5593708, Idaho 5596512 83619
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83687
Post Falls 5604353, Idaho 5596512 83854
Sandpoint 5606401, Idaho 5596512 83864
Aurora 4883817, Illinois 4896861 60504
Aurora 4883817, Illinois 4896861 60506
Barrington 4884116, Illinois 4896861 60010
Site Public Contact
847-842-4847
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carterville 4235311, Illinois 4896861 62918
Carthage 4886716, Illinois 4896861 62321
Chicago 4887398, Illinois 4896861 60611
Chicago 4887398, Illinois 4896861 60612
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-355-3046
Chicago 4887398, Illinois 4896861 60657
Site Public Contact
773-296-5360
Crystal Lake 4889229, Illinois 4896861 60014
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
DeKalb 4889553, Illinois 4896861 60115
Dixon 4889959, Illinois 4896861 61021
Site Public Contact
815-285-7800
Downers Grove 4890119, Illinois 4896861 60515
Effingham 4237727, Illinois 4896861 62401
Elgin 4890864, Illinois 4896861 60123
Site Public Contact
847-429-2907
Elmhurst 4891010, Illinois 4896861 60126
Eureka 4891310, Illinois 4896861 61530
Galesburg 4893392, Illinois 4896861 61401
Geneva 4893591, Illinois 4896861 60134
Glenview 4893886, Illinois 4896861 60026
Site Public Contact
312-695-1102
Grayslake 4894465, Illinois 4896861 60030
Site Public Contact
312-695-1102
Hazel Crest 4895416, Illinois 4896861 60429
Site Public Contact
708-799-9995
Kewanee 4898433, Illinois 4896861 61443
Lake Forest 4899012, Illinois 4896861 60045
Libertyville 4899739, Illinois 4896861 60048
Libertyville 4899739, Illinois 4896861 60048
Macomb 4900817, Illinois 4896861 61455
Naperville 4903279, Illinois 4896861 60540
Site Public Contact
630-646-6075
O'Fallon 4245926, Illinois 4896861 62269
Oak Brook 4904277, Illinois 4896861 60523
Oak Lawn 4904365, Illinois 4896861 60453-2699
Site Public Contact
800-323-8622
Oak Lawn 4904365, Illinois 4896861 60453
Orland Park 4904937, Illinois 4896861 60462
Ottawa 4905006, Illinois 4896861 61350
Palos Heights 4905259, Illinois 4896861 60463
Park Ridge 4905367, Illinois 4896861 60068
Site Public Contact
847-384-3621
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peru 4905770, Illinois 4896861 61354
Plainfield 4906125, Illinois 4896861 60585
Princeton 4906818, Illinois 4896861 61356
Shiloh 4249910, Illinois 4896861 62269
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Warrenville 4915525, Illinois 4896861 60555
Washington 4915545, Illinois 4896861 61571
Yorkville 4917298, Illinois 4896861 60560
Avon 4254021, Indiana 4921868 46123
Carmel 4255466, Indiana 4921868 46032
Indianapolis 4259418, Indiana 4921868 46202
Indianapolis 4259418, Indiana 4921868 46202
Ames 4846834, Iowa 4862182 50010
Site Public Contact
515-956-4132
Ames 4846834, Iowa 4862182 50010
Boone 4849051, Iowa 4862182 50036
Site Public Contact
515-956-4132
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-365-4673
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-363-2690
Fort Dodge 4857486, Iowa 4862182 50501
Site Public Contact
515-956-4132
Jefferson 4862482, Iowa 4862182 50129
Site Public Contact
515-956-4132
Marshalltown 4866371, Iowa 4862182 50158
Site Public Contact
515-956-4132
Louisville 4299276, Kentucky 6254925 40202
Site Public Contact
502-562-3429
Louisville 4299276, Kentucky 6254925 40207
Louisville 4299276, Kentucky 6254925 40245
New Orleans 4335045, Louisiana 4331987 70121
Brewer 4959233, Maine 4971068 04412
Site Public Contact
800-987-3005
Cumberland 4352681, Maryland 4361885 21502
Site Public Contact
240-964-1400
Boston 4930956, Massachusetts 6254926 02215
Site Public Contact
877-442-3324
Burlington 4931737, Massachusetts 6254926 01805
Foxborough 4937222, Massachusetts 6254926 02035
Site Public Contact
877-338-7425
Methuen 4943828, Massachusetts 6254926 01844
Site Public Contact
877-338-7425
Milford 4943958, Massachusetts 6254926 01757
Site Public Contact
877-332-4294
Peabody 4946863, Massachusetts 6254926 01960
South Weymouth 4951568, Massachusetts 6254926 02190
Site Public Contact
781-624-5000
Battle Creek 4985153, Michigan 5001836 49017
Brighton 4986994, Michigan 5001836 48114
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Escanaba 4992232, Michigan 5001836 49829
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Grand Rapids 4994358, Michigan 5001836 49503
Grand Rapids 4994358, Michigan 5001836 49503
Kalamazoo 4997787, Michigan 5001836 49007
Kalamazoo 4997787, Michigan 5001836 49007
Lansing 4998830, Michigan 5001836 48912
Livonia 4999837, Michigan 5001836 48154
Muskegon 5003132, Michigan 5001836 49444
Niles 5003514, Michigan 5001836 49120
Site Public Contact
616-391-1230
Norton Shores 5004005, Michigan 5001836 49444
Pontiac 5006166, Michigan 5001836 48341
Reed City 5006946, Michigan 5001836 49677
Saint Joseph 5008327, Michigan 5001836 49085
Saint Joseph 5008327, Michigan 5001836 49085
Traverse City 5012495, Michigan 5001836 49684
Wyoming 5015618, Michigan 5001836 49519
Ypsilanti 5015688, Michigan 5001836 48197
Bemidji 5017822, Minnesota 5037779 56601
Brainerd 5019116, Minnesota 5037779 56401
Burnsville 5019767, Minnesota 5037779 55337
Coon Rapids 5022025, Minnesota 5037779 55433
Deer River 5024099, Minnesota 5037779 56636
Duluth 5024719, Minnesota 5037779 55805
Edina 5025264, Minnesota 5037779 55435
Hibbing 5030005, Minnesota 5037779 55746
Site Public Contact
218-786-3308
Maplewood 5036588, Minnesota 5037779 55109
Minneapolis 5037649, Minnesota 5037779 55407
Minneapolis 5037649, Minnesota 5037779 55415
Saint Cloud 5044407, Minnesota 5037779 56303
Saint Louis Park 5045021, Minnesota 5037779 55416
Saint Paul 5045360, Minnesota 5037779 55101
Saint Paul 5045360, Minnesota 5037779 55102
Sandstone 5045908, Minnesota 5037779 55072
Shakopee 5046997, Minnesota 5037779 55379
Virginia 5051468, Minnesota 5037779 55792
Woodbury 5053358, Minnesota 5037779 55125
Columbus 4422442, Mississippi 4436296 39705
Grenada 4428539, Mississippi 4436296 38901
Jackson 4431410, Mississippi 4436296 39216
Site Public Contact
601-815-6700
New Albany 4438121, Mississippi 4436296 38652
Oxford 4440076, Mississippi 4436296 38655
Southhaven 4446702, Mississippi 4436296 38671
Cape Girardeau 4379966, Missouri 4398678 63703
City of Saint Peters 4407237, Missouri 4398678 63376
Creve Coeur 4382837, Missouri 4398678 63141
Farmington 4386289, Missouri 4398678 63640
Site Public Contact
314-996-5569
Sainte Genevieve 4407294, Missouri 4398678 63670
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63110
St Louis 4407066, Missouri 4398678 63128
St Louis 4407066, Missouri 4398678 63129
St Louis 4407066, Missouri 4398678 63131
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63136
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Sullivan 4410669, Missouri 4398678 63080
Site Public Contact
314-996-5569
Sunset Hills 4410836, Missouri 4398678 63127
Site Public Contact
314-996-5569
Anaconda 5637146, Montana 5667009 59711
Billings 5640350, Montana 5667009 59101
Bozeman 5641727, Montana 5667009 59715
Great Falls 5655240, Montana 5667009 59405
Kalispell 5660340, Montana 5667009 59901
Missoula 5666639, Montana 5667009 59804
Lebanon 5088597, New Hampshire 5090174 03756
Basking Ridge 5095409, New Jersey 5101760 07920
Site Public Contact
212-639-7592
Cherry Hill 4501198, New Jersey 5101760 08002
Hackensack 5098706, New Jersey 5101760 07601
Site Public Contact
551-996-2897
Hamilton 5098765, New Jersey 5101760 08690
Site Public Contact
609-631-6946
Long Branch 5100619, New Jersey 5101760 07740
Middletown 5101170, New Jersey 5101760 07748
Site Public Contact
212-639-7592
Montvale 5101361, New Jersey 5101760 07645
Site Public Contact
212-639-7592
Morristown 5101427, New Jersey 5101760 07960
Site Public Contact
973-971-5900
New Brunswick 5101717, New Jersey 5101760 08903
Site Public Contact
732-235-7356
Newark 5101798, New Jersey 5101760 07101
Site Public Contact
732-235-7356
Sewell 4504048, New Jersey 5101760 08080
Somerville 5104774, New Jersey 5101760 08876
Summit 5105127, New Jersey 5101760 07902
Site Public Contact
908-522-2043
Buffalo 5110629, New York 5128638 14263
Camillus 4833098, New York 5128638 13031
Site Public Contact
315-472-7504
Commack 5113412, New York 5128638 11725
Site Public Contact
212-639-7592
East Syracuse 5116079, New York 5128638 13057
Site Public Contact
315-472-7504
Glens Falls 5118693, New York 5128638 12801
Site Public Contact
518-926-6700
Harrison 5120095, New York 5128638 10604
Site Public Contact
212-639-7592
New York 5128581, New York 5128638 10065
Site Public Contact
212-639-7592
The Bronx 5110266, New York 5128638 10461
Uniondale 5141927, New York 5128638 11553
Site Public Contact
212-639-7592
Cary 4459467, North Carolina 4482348 27518
Chapel Hill 4460162, North Carolina 4482348 27599
Durham 4464368, North Carolina 4482348 27710
Site Public Contact
888-275-3853
Pinehurst 4485272, North Carolina 4482348 28374
Raleigh 4487042, North Carolina 4482348 27609
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58103
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Avon 5146277, Ohio 5165418 44011
Site Public Contact
800-641-2422
Beachwood 5146711, Ohio 5165418 44122
Canton 5149222, Ohio 5165418 44710
Cleveland 5150529, Ohio 5165418 44106
Columbus 4509177, Ohio 5165418 43210
Kettering 4515843, Ohio 5165418 45429
Mentor 5162645, Ohio 5165418 44060
Lawton 4540737, Oklahoma 4544379 73505
Site Public Contact
877-231-4440
Oklahoma City 4544349, Oklahoma 4544379 73104
Newberg 5742726, Oregon 5744337 97132
Oregon City 5744253, Oregon 5744337 97045
Portland 5746545, Oregon 5744337 97213
Portland 5746545, Oregon 5744337 97225
Portland 5746545, Oregon 5744337 97239
Allentown 5178127, Pennsylvania 6254927 18103
Beaver 5179446, Pennsylvania 6254927 15009
Bethlehem 5180225, Pennsylvania 6254927 18017
Butler 5182534, Pennsylvania 6254927 16001
Danville 5186327, Pennsylvania 6254927 17822
Dickson City 5186924, Pennsylvania 6254927 18519
East Stroudsburg 5188075, Pennsylvania 6254927 18301
Erie 5188843, Pennsylvania 6254927 16505
Greensburg 5192029, Pennsylvania 6254927 15601
Site Public Contact
724-838-1900
Harrisburg 5192726, Pennsylvania 6254927 17109
Hazleton 5193011, Pennsylvania 6254927 18201
Hazleton 5193011, Pennsylvania 6254927 18201
Johnstown 5195561, Pennsylvania 6254927 15901
Site Public Contact
814-534-4724
Lewisburg 5197842, Pennsylvania 6254927 17837
Mechanicsburg 5200657, Pennsylvania 6254927 17050
Monroeville 5201734, Pennsylvania 6254927 15146
Philadelphia 4560349, Pennsylvania 6254927 19107
Philadelphia 4560349, Pennsylvania 6254927 19114
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-647-8073
Pittsburgh 5206379, Pennsylvania 6254927 15237
Site Public Contact
412-367-6454
Pittsburgh 5206379, Pennsylvania 6254927 15243
Site Public Contact
412-502-3920
Scranton 5211303, Pennsylvania 6254927 18510
Wilkes-Barre 5219488, Pennsylvania 6254927 18711
Williamsport 5219585, Pennsylvania 6254927 17754
Westerly 5225631, Rhode Island 5224323 02891
Boiling Springs 4571805, South Carolina 4597040 29316
Charleston 4574324, South Carolina 4597040 29425
Easley 4577263, South Carolina 4597040 29640
Georgetown 4579662, South Carolina 4597040 29440
Greenville 4580543, South Carolina 4597040 29605
Greenville 4580543, South Carolina 4597040 29605
Greenville 4580543, South Carolina 4597040 29615
Greer 4580599, South Carolina 4597040 29650
Seneca 4595346, South Carolina 4597040 29672
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Collierville 4614748, Tennessee 4662168 38017
Memphis 4641239, Tennessee 4662168 38120
Nashville 4644585, Tennessee 4662168 37232
Site Public Contact
800-811-8480
Amarillo 5516233, Texas 4736286 79106
Baytown 4672731, Texas 4736286 77521
Cypress 4684724, Texas 4736286 77429
Houston 4699066, Texas 4736286 77030
Site Public Contact
713-790-2700
Houston 4699066, Texas 4736286 77070
Houston 4699066, Texas 4736286 77094
Site Public Contact
832-522-2873
Nassau Bay 4713813, Texas 4736286 77058
Sugar Land 4734825, Texas 4736286 77479
Site Public Contact
281-242-2873
The Woodlands 4736476, Texas 4736286 77385
Burlington 5234372, Vermont 5242283 05401
Burlington 5234372, Vermont 5242283 05405
Mechanicsville 4772566, Virginia 6254928 23116
Midlothian 4772943, Virginia 6254928 23114
Richmond 4781708, Virginia 6254928 23223
Richmond 4781708, Virginia 6254928 23226
Richmond 4781708, Virginia 6254928 23235
Richmond 4781708, Virginia 6254928 23298
Bridgeport 4800081, West Virginia 4826850 26330
Charleston 4801859, West Virginia 4826850 25304
Site Public Contact
304-388-9944
Martinsburg 4813878, West Virginia 4826850 25401
Morgantown 4815352, West Virginia 4826850 26506
Parkersburg 4817641, West Virginia 4826850 26101
Appleton 5244080, Wisconsin 5279468 54911
Ashland 5244247, Wisconsin 5279468 54806
Burlington 5247214, Wisconsin 5279468 53105
Cudahy 5249871, Wisconsin 5279468 53110
Germantown 5254218, Wisconsin 5279468 53022
Grafton 5254739, Wisconsin 5279468 53024
Green Bay 5254962, Wisconsin 5279468 54301
Green Bay 5254962, Wisconsin 5279468 54303
Green Bay 5254962, Wisconsin 5279468 54311
Kenosha 5258393, Wisconsin 5279468 53142
La Crosse 5258957, Wisconsin 5279468 54601
Marinette 5261852, Wisconsin 5279468 54143
Menomonee Falls 5262630, Wisconsin 5279468 53051
Site Public Contact
262-257-5100
Milwaukee 5263045, Wisconsin 5279468 53209
Milwaukee 5263045, Wisconsin 5279468 53215
Milwaukee 5263045, Wisconsin 5279468 53226
Site Public Contact
414-805-3666
Milwaukee 5263045, Wisconsin 5279468 53233
Mukwonago 5263965, Wisconsin 5279468 53149
Oak Creek 5265228, Wisconsin 5279468 53154
Site Public Contact
414-805-0505
Oconomowoc 5265499, Wisconsin 5279468 53066
Site Public Contact
262-928-7878
Oconto Falls 5265522, Wisconsin 5279468 54154
Oshkosh 5265838, Wisconsin 5279468 54904
Racine 5268249, Wisconsin 5279468 53406
Sheboygan 5272893, Wisconsin 5279468 53081
Sheboygan 5272893, Wisconsin 5279468 53081
Sheboygan 5272893, Wisconsin 5279468 53081
Sturgeon Bay 5274867, Wisconsin 5279468 54235-1495
Summit, Wisconsin 5279468 53066
Two Rivers 5276609, Wisconsin 5279468 54241
Waukesha 5278052, Wisconsin 5279468 53188
Site Public Contact
262-928-7632
Waukesha 5278052, Wisconsin 5279468 53188
Wauwatosa 5278159, Wisconsin 5279468 53226
West Allis 5278420, Wisconsin 5279468 53227
West Bend 5278422, Wisconsin 5279468 53095
Site Public Contact
414-805-0505
More Details
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
PRIMARY OBJECTIVE: I. To compare disease free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. SECONDARY OBJECTIVES: I. To compare overall survival (OS) for patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. II. To assess adverse events in each study arm by Common Terminology Criteria for Adverse Events (CTCAE) 5.0. BIOBANKING OBJECTIVE: I. To bank specimens for future unspecified research. QUALITY OF LIFE (QOL) OBJECTIVES: I. To compare global quality of life (QOL) for patients treated with pembrolizumab and tivozanib versus those receiving pembrolizumab alone. II. To compare patient-reported fatigue for patients treated with pembrolizumab and tivozanib versus those receiving pembrolizumab alone. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive pembrolizumab intravenously (IV) on days 1 and 43 of each cycle, or on days 1, 22, 43 and 64 of each cycle. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and magnetic resonance imaging (MRI) or computed tomography (CT) throughout the trial and may undergo tissue biopsy on study. ARM II: Patients receive pembrolizumab IV on days 1 and 43 of each cycle and tivozanib orally (PO) once daily (QD) on days 1-21, days 29-49, and days 57-77 of each cycle for up to 6 months. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study. After completion of study treatment, patients are followed up every 4 months for 2 years, then every 6 months for 3 years, then every subsequent year for 5 years.